Navigation Links
Aeolus Pharmaceuticals' AEOL 10150 Highlighted in Nature Genetics,Publication

LAGUNA NIGUEL, Calif.--(BUSINESS WIRE)--Apr 18, 2007 - Aeolus Pharmaceuticals, Inc. (OTCBB:AOLS) announced today that a new report published in the medical journal, Nature Genetics (Tong et al. Nature Genetics 39:476-485, 2007), showed that Aeolus Pharmaceuticals' lead compound AEOL 10150 (MnTDEIP) can improve survival in fruit flies genetically lacking the neurofibromatosis-1 (NF1) gene. These mutant flies had reduced mitochondrial function and increased production of reactive oxygen species that was associated with a greatly shortened lifespan. Dr. Douglas Wallace's team at the University of California-Irvine concluded that the increased mitochondrial Reactive Oxygen Species (ROS) production resulting from NF1 mutations could be an important factor in the generation of neurofibromas. If so, then the suppression of mitochondrial ROS production through the treatment with catalytic antioxidants such as AEOL 10150 may provide a powerful new approach to treat NF1, as well as other cancers.

Many common neurodegenerative diseases including Parkinson's disease, Amyotrophic lateral sclerosis (ALS), and Alzheimer's disease are often associated with mitochondrial dysfunction and the overproduction of reactive oxygen species. Neurofibromatosis is a common neurogenetic disorder that afflicts 1 in 3,000 people worldwide. Humans that harbor mutant neurofibromatous-1 genes are at increased risk of developing cancer and often have learning disabilities and developmental abnormalities.

AEOL 10150 has been shown to be safe and well-tolerated in both a single and a multi-dose phase 1 studies. In animal models, the compound has shown promise in ALS, protection of healthy cells from radiation therapy, Parkinson's disease, stroke and neurofibromatosis, among other indications. The Company is currently in the process of planning and securing the financial resources to support a phase 2 study to test the efficacy of AEOL 10150 in humans.

About Aeolus Pharmaceuticals

Aeolus is developing a variety of therapeutic agents based on its proprietary small molecule catalytic antioxidants, with AEOL 10150 being the first to enter human clinical evaluation. AEOL 10150 is a patented, small molecule catalytic antioxidant that has shown the ability to scavenge a broad range of reactive oxygen species, or free radicals. As a catalytic antioxidant, AEOL 10150 mimics and thereby amplifies the body's natural enzymatic systems for eliminating these damaging compounds. Because oxygen-derived free radicals are believed to have an important role in the pathogenesis of many diseases, Aeolus' catalytic antioxidants are believed to have a broad range of potential therapeutic uses.

The statements in this press release that are not purely statements of historical fact are forward-looking statements. Such statements include, but are not limited to, those relating to Aeolus' product candidates, as well as its proprietary technologies and research programs. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Aeolus' actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. Important factors that could cause results to differ include risks associated with uncertainties of progress and timing of clinical trials, scientific research and product development activities, difficulties or delays in development, testing, obtaining regulatory approval, the need to obtain funding for pre-clinical and clinical trials and operations, the scope and validity of intellectual property protection for Aeolus' product candidates, proprietary technologies and their uses, and competition from other biopharmaceutical companies. Certain of these factors and others are more fully described in Aeolus' filings with the Securities and Exchange Commission, including, but not limite d to, Aeolus' Quarterly Report on Form 10-Q for the quarter ended December 31, 2006. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof.

Contact

Aeolus Pharmaceuticals, Inc.
John L. McManus, President and Chief Executive Officer
1-949-481-9825


'"/>




Related medicine technology :

1. Study Demonstrating Aeolus Compounds Neuroprotection in Parkinsons Disease Published in the Journal of Neuroscience
2. Aeolus Pharmaceuticals AEOL 10113 May Play an Important Role Regulating the Oxidative Damage Induced by Ionizing Radiation
3. Aeolus Pharmaceuticals AEOL 10113 Demonstrates Potential as a Protector of Healthy Normal Cells from Cancer Radiation Therapy
4. Aeolus Pharmaceuticals Announces Successful Completion of Multiple Dose Safety Study of AEOL 10150
5. Faust Pharmaceuticals Phase IIa Results for Parkinsons Disease Presented at International Congress of Parkinsons Disease and Movement Disorders
6. Data from Rexahn Pharmaceuticals Phase I Trial of RX-0201 (Archexin) to Be Presented at the 43rd American Society of Clinical Oncology Annual Meeting in Chicago
7. VGX Pharmaceuticals Novel HIV and Pandemic Influenza DNA Vaccine Candidates Trigger Robust Immune Responses and Protection in Pre-Clinical Models
8. ACADIA Pharmaceuticals Schizophrenia Programs to Be Presented at the 2007 International Congress on Schizophrenia Research
9. Positive Results for Second-Generation Taxus Liberte Coronary Stent System Highlighted in Journal of American College of Cardiology
10. Isotechnikas Lead Drug, ISA247, To Be Highlighted at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
11. Gentiums Defibrotide Highlighted in Poster Presentation at World Congress of Nephrology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... , May 26, 2016   ... software and analytics, network solutions and technology-enabled ... announced it entered into a strategic channel ... of outpatient software solutions and revenue cycle ... specialty hospitals and rehabilitation clinics to optimize ...
(Date:5/25/2016)... Germany and GERMANTOWN, Maryland ... N.V. (NASDAQ: QGEN ; Frankfurt Prime Standard: QIA) ... and co-development agreement with Therawis Diagnostics GmbH to develop and ... to develop and market PITX2 as a marker to predict ... breast cancer patients. "We are pleased to partner ...
(Date:5/25/2016)... CHESTERFIELD, Va. , May 25, 2016 /PRNewswire/ ... next-generation sequencing test for wounds and infections. This ... ALL parasites, and select viruses. The test requires ... area. David G. Bostwick ... molecular testing to facilitate wound healing: "We are ...
Breaking Medicine Technology:
(Date:5/26/2016)... (PRWEB) , ... May 26, 2016 , ... Bunion ... knowns as a bunionette) treatment was more than humbled by customer demand over the ... of their SKU's mid sale. Now that Bunion Bootie has completely replenished its inventory ...
(Date:5/26/2016)... ... May 26, 2016 , ... On May 23rd during the National Eye ... and international water advocate, was honored by Ashram, Inc. as the world’s foremost water ... knelt on the banks of the Nile to fill their red clay pots with ...
(Date:5/26/2016)... ... May 26, 2016 , ... The introduction of our professional athletes coincides ... HEAD ™”. , “We are proud to introduce Meghan Klingenberg, defender and ... have Brian Quick, wide receiver for Los Angeles who was a second round selection ...
(Date:5/26/2016)... ... May 26, 2016 , ... ... Morrow-Fox . With over 20 years of experience in leading technology and human ... several years of university teaching, Morrow-Fox will be featured on Metcalf’s VoiceAmerica ...
(Date:5/26/2016)... NY (PRWEB) , ... May 26, 2016 , ... May ... lips been so central to popular cosmetic improvement efforts. Record numbers of clients now ... appear more prominent or pouty, says Kally Papantoniou, MD, of Advanced Dermatology P.C. ...
Breaking Medicine News(10 mins):